Business Wire

NY-MHW-LTD

16.11.2021 16:02:11 CET | Business Wire | Press release

Share
MHW Expands Global Wine Importation and Distribution Footprint Through Acquisition of USA Wine West and USA Wine Imports

MHW, Ltd., the leading service provider for wine, spirits, beer and cider in the United States, has announce the successful acquisition of two nationally licensed importation companies, USA Wine West and USA Wine Imports, each of whom have decades of experience in fine wine distribution, logistics management, market strategy, compliance and administration.

“Over the last 25 years, USA Wine West has provided unparalleled logistics, compliance and administrative import services to foreign and domestic wineries who launch in the U.S.,” says Founder Steve Melchiskey, who will continue leading the USA Wine West team and join MHW as Vice President of Sales and Development. “Becoming a part of MHW enables us to carry on that mission with greater resources and capabilities. This is especially exciting for the passionate wineries and individuals we work with, as well as our world-class team who has been critical to this success.”

MHW, USA Wine West and USA Wine Imports will continue to service their respective client portfolios while they explore additional ways to deliver value through their partnership with clients over time by expanding on service capabilities, such as global consolidated logistics and more comprehensive direct-to-retail offerings.

“MHW is thrilled to welcome USA Wine West and USA Wine Imports to our team,” says MHW Chief Executive Officer Gabe Barkley. “Both companies enhance our leadership in serving the needs of the global fine wine market across all segments. We share a common DNA of building and valuing lasting client relationships. That orientation toward partnership is vital to our ongoing success. Because my career began in fine wine retail, I am personally thrilled about our expanded ability to help wine producers – from family-owned wineries to private-label programs – establish their presence in the U.S. market alongside our existing leadership positions in spirits and malt beverages.”

“It has been gratifying and humbling to have presided over a period of incredible growth at USA Wine Imports and we are very excited to be passing the baton to such a capable partner in MHW,” says former USA Wine Imports Vice President Nicolas Mestre. “This partnership will allow our portfolios the additional resources they require to scale and thrive in the market.” Sandi Bartel, USA Wine’s longtime General Manager, will continue to manage day-to-day operations.

About MHW, LTD.

MHW, LTD . is the leading beverage alcohol service partner in the United States, European Union and United Kingdom, specializing in strategic, scalable back-office solutions including compliance management, licensing, operations, logistics, fulfillment, accounting, business insight reporting, and technology. Since 1995, MHW has served as the national importer and distributor to international brands of all sizes, helping more than 100,000 wine, spirits and beer products successfully enter the U.S. MHW’s global wholesale capabilities give clients access to the retail trade in four key U.S. markets, the EU and UK. Companies who partner with MHW have the competitive advantage to focus time and effort on building brand sales. With strategic and attentive teams who have decades of back-office beverage alcohol experience, MHW offers unparalleled expertise and service excellence. To learn how to make your mark in the US and EU, please visit mhwltd.com .

About USA Wine West

USA Wine West is a premier provider of national wine import services in the U.S. A fully licensed federal importer, they work in partnership with the sales and marketing teams of foreign and domestic wineries to distribute wine to wholesalers in all 50 states. They work strategically with client portfolios to provide a cost-effective, integrated sales platform, along with an efficient logistical and compliance system designed to support foreign wineries to succeed in this competitive market.

About USA Wine Imports

USA Wine Imports is a national importer of wine and spirits providing wholesale customers distribution in all major wine markets in the U.S. USA Wine Imports works closely with wine and spirits producers, importers, brokers and agents to develop innovative sales and marketing strategies and meet ambitious sales goals in a crowded marketplace. In addition, they handle import, freight, compliance, licensing, warehousing, order fulfillment, invoicing, inventory control and accounting services.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye